C. Dayan

发表

EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1)

I. Litchfield, P. Narendran, F. Boardman, 2022, BMJ Open Diabetes Research & Care.

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.

M. Knip, W. Hagopian, A. Ziegler, 2022, Diabetes.

Immunotherapy for type 1 diabetes.

L. Allen, C. Dayan, 2018, British medical bulletin.

Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy.

M. Stefanidou, M. Peakman, J. Mous, 2019, International journal of pharmaceutics.

Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes

D. Tatović, C. Dayan, 2021, Diabetic medicine : a journal of the British Diabetic Association.

Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study

T. Donner, P. Ambery, J. Donaldson, 2014, Diabetic medicine : a journal of the British Diabetic Association.

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes

F. Wong, Martina A. McAteer, J. Ludvigsson, 2022, Immunotherapy advances.

Responses after Skin Antigen Node: A Novel Tool for the Monitoring of Fine-Needle Aspiration Biopsy of the Lymph

F. Wong, Y. Levin, E. Kochba, 2015 .

Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes

P. Linsley, L. Dimeglio, K. Herold, 2022, Diabetes care.

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study

F. Wong, M. Peakman, L. James, 2009, Clinical and experimental immunology.

Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium

R. Leslie, K. Gillespie, A. E. Long, 2022, Diabetic medicine : a journal of the British Diabetic Association.

Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides.

Sion A. Coulman, F. Wong, B. Malissen, 2020, Nanomedicine : nanotechnology, biology, and medicine.

Hydrodynamic gene delivery in human skin using a hollow microneedle device

Sion A. Coulman, M. Stefanidou, C. O’Mahony, 2017, Journal of controlled release : official journal of the Controlled Release Society.

T Cell Activation by Coxsackievirus B4 Antigens in Type 1 Diabetes Mellitus: Evidence for Selective TCR V Usage Without Superantigenic Activity

G. Sgarbi, Wedderburn, J. Tremble, 2001 .

IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes

F. Wong, C. Dayan, J. Fu, 2010, Diabetologia.

Insights From Single Cell RNA Sequencing Into the Immunology of Type 1 Diabetes- Cell Phenotypes and Antigen Specificity

Terri C. Thayer, S. Hanna, D. Tatović, 2021, Frontiers in Immunology.

Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative

F. Wong, C. Boitard, E. James, 2011, Diabetes/metabolism research and reviews.

Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data

P. Taylor, R. French, K. Haines, 2022, Diabetic medicine : a journal of the British Diabetic Association.

Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol

J. Gregory, A. Marwaha, T. Tree, 2021, BMJ Open.

A perspective on treating type 1 diabetes mellitus before insulin is needed

P. Narendran, D. Tatović, C. Dayan, 2023, Nature Reviews Endocrinology.

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

E. Bonifacio, M. Knip, D. Dunger, 2022, Trials.

Gene expression signature predicts rate of type 1 diabetes progression

Maria K. Jaakkola, E. Bonifacio, C. de Beaufort, 2023, EBioMedicine.

National Trends in Hyperglycemia and Diabetic Ketoacidosis in Children, Adolescents, and Young Adults With Type 1 Diabetes: A Challenge Due to Age or Stage of Development, or Is New Thinking About Service Provision Needed?

J. Warner, N. Holman, B. Young, 2023, Diabetes care.

Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans

R. Andrews, F. Wong, Martina A. McAteer, 2023, medRxiv.

Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial

M. Peakman, C. Dayan, Yuk-Fun Liu, 2013 .

Sedentary time and markers of inflammation in people with newly diagnosed type 2 diabetes

T. Peters, A. Cooper, A. Page, 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial

A. Montgomery, J. Bright, K. Coulman, 2011, The Lancet.

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

K. Owen, C. Boitard, M. Kindermans, 2023, BMC Medicine.

Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes.

L. Wen, F. Wong, J. Birchall, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes.

Sion A. Coulman, F. Wong, J. Birchall, 2016, Journal of controlled release : official journal of the Controlled Release Society.